LIVIVO - Search results -

Search results

Result 1 - 10 of total 17

Search options

Article ; Online: Sofosbuvir as a potential option for the treatment of COVID-19.

Nourian, Anahid / Khalili, Hossein

2020 Volume 91, Issue 2, Page(s) 236–238

Abstract: Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a ... ...

Abstract	Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies.
MeSH term(s)	Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; Coronavirus Infections/drug therapy ; Humans ; Pandemics ; Pneumonia, Viral/drug therapy ; Sofosbuvir/therapeutic use
Chemical Substances	Antiviral Agents ; Sofosbuvir (WJ6CA3ZU8B)
Keywords	covid19
Language	English
Publishing date	2020-05-11
Publishing country	Italy
Document type	Letter
ZDB-ID	2114240-3
ISSN	2531-6745 ; 0392-4203
ISSN (online)	2531-6745
ISSN	0392-4203
DOI	10.23750/abm.v91i2.9609
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 925: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Treatment of nosocomial infections in intensive care unit with colistin and polymyxin B.

Nourian, Anahid / Kargar, Mona

International journal of clinical pharmacy

2019 Volume 41, Issue 6, Page(s) 1398–1399

MeSH term(s)	Anti-Bacterial Agents ; Colistin ; Cross Infection ; Economics, Pharmaceutical ; Humans ; Intensive Care Units ; Polymyxin B
Chemical Substances	Anti-Bacterial Agents ; Polymyxin B (J2VZ07J96K) ; Colistin (Z67X93HJG1)
Language	English
Publishing date	2019-10-24
Publishing country	Netherlands
Document type	Letter ; Comment
ZDB-ID	2601204-2
ISSN	2210-7711 ; 2210-7703 ; 0928-1231
ISSN (online)	2210-7711
ISSN	2210-7703 ; 0928-1231
DOI	10.1007/s11096-019-00921-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Sofosbuvir as a potential option for the treatment of COVID-19

Nourian, Anahid / Khalili, Hossein

Acta Biomed

Abstract	Sofosbuvir may be a potential option in the treatment of COVID-19 based on the similarity between the replication mechanisms of the HCV and the coronavirus. According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #322186
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review.

Dashti-Khavidaki, Simin / Khalili, Hossein / Nourian, Anahid

Iranian journal of kidney diseases

2020 Volume 14, Issue 4, Page(s) 247–255

Abstract: Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here. Literature review was done for several pharmacotherapy aspects in CKD patients including selection and ... ...

Abstract	Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here. Literature review was done for several pharmacotherapy aspects in CKD patients including selection and modification of COVID-19 treatment, drug interactions, nephrotoxicity of drugs that are used for treatment of COVID-19 and potential risks/benefits of routine medications of CKD patients during COVID-19 pandemic. CKD patients should be treated according to local or national COVID-19 protocols as other patients. But, there is no data on using remdesivir in patients with severe CKD. Oseltamivir and ribavirin require dose modification in patients with moderate to severe CKD. Nephrolithiasis, CKD, and acute interstitial nephritis have been reported with protease inhibitors. Acute kidney injury has been reported with remdesivir in patients with severe COVID-19. Pharmacokinetic-enhanced protease inhibitors increase the concentration of some drugs such as statins, cinacalcet, steroids, calcineurin inhibitors (CNIs). Some hypothetical benefits and harms have been suggested for statins and renin-angiotensinaldosterone system inhibitors in COVID-19 patients. Continuing guideline-directed administration of these drugs is recommended. Among different immunomodulating/immunosuppressive drugs, hydroxychloroquine and CNIs are the safest ones during COVID-19. Antimetabolites are suggested to be withheld during moderate to severe COVID-19. Fluid therapy and anticoagulant prophylaxis/ treatment need special attention in CKD patients with COVID-19. CKD patients with COVID-19 are treated as other patients, with some dose modifications if needed. Be mindful for management of drug interactions as well as modification of immunosuppressive drugs in patients with moderate to severe COVID-19.
MeSH term(s)	Betacoronavirus/isolation & purification ; Comorbidity ; Coronavirus Infections/classification ; Coronavirus Infections/complications ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Humans ; Pandemics ; Patient Selection ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Renal Insufficiency, Chronic/drug therapy ; Renal Insufficiency, Chronic/epidemiology ; Risk Assessment
Keywords	covid19
Language	English
Publishing date	2020-06-20
Publishing country	Iran
Document type	Journal Article ; Review
ZDB-ID	2388271-2
ISSN	1735-8604 ; 1735-8582
ISSN (online)	1735-8604
ISSN	1735-8582
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Superior Mesenteric Venous (SMV) Thrombosis Accompanied with Appendicitis in a Patient with Primary Diagnosis of Typhoid Fever.

Adibimehr, Alireza / SeyedAlinaghi, SeyedAhmad / Nourian, Anahid / Mehrabi, Zeinab / Moslemi, Rohollah

Infectious disorders drug targets

2020 Volume 21, Issue 4, Page(s) 634–636

Abstract: Background: Septic thrombophlebitis of the Superior Mesenteric Venous (SMV) is rarely accompanied by appendicitis, and symptoms are atypical, so the diagnosis is commonly delayed, resulting in it is associated with high mortality.: Case presentation: ...

Abstract	Background: Septic thrombophlebitis of the Superior Mesenteric Venous (SMV) is rarely accompanied by appendicitis, and symptoms are atypical, so the diagnosis is commonly delayed, resulting in it is associated with high mortality. Case presentation: We report a case of neglected SMV septic thrombophlebitis is caused by appendicitis. The patient represented with fever, vague abdominal pain without rebound tenderness, and history of the consumption of contaminated water. Antibiotic initiated due to suspicious typhoid fever. Then typhoid fever was ruled out. Computed tomography (CT) scans revealed micro-abscess forming complicated appendicitis and the thrombus in SMV. Discussion and conclusion: The patient underwent a laparoscopic appendectomy, during which retrocecal gangrened perforated appendix with a 2×2 cm abscess was drained. Based on positive culture with ESBL organism meropenem was initiated. Appendectomy and treatment with broad- -spectrum antibiotics and anticoagulation led to a full recovery.
MeSH term(s)	Appendectomy ; Appendicitis/diagnosis ; Appendicitis/diagnostic imaging ; Humans ; Mesenteric Veins/diagnostic imaging ; Thrombophlebitis ; Typhoid Fever/complications ; Typhoid Fever/diagnosis
Language	English
Publishing date	2020-09-04
Publishing country	United Arab Emirates
Document type	Case Reports
ZDB-ID	2234298-9
ISSN	2212-3989 ; 1871-5265
ISSN (online)	2212-3989
ISSN	1871-5265
DOI	10.2174/1871526520666200731180042
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5598: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review

Dashti-Khavidaki, Simin / Khalili, Hossein / Nourian, Anahid

Iranian journal of kidney diseases

Abstract: Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here Literature review was done for several pharmacotherapy aspects in CKD patients including selection and ... ...

Abstract	Treatment of coronavirus disease 2019 (COVID-19) among patients with CKD requires special pharmacotherapy considerations that are reviewed here Literature review was done for several pharmacotherapy aspects in CKD patients including selection and modification of COVID-19 treatment, drug interactions, nephrotoxicity of drugs that are used for treatment of COVID-19 and potential risks/benefits of routine medications of CKD patients during COVID-19 pandemic CKD patients should be treated according to local or national COVID-19 protocols as other patients But, there is no data on using remdesivir in patients with severe CKD Oseltamivir and ribavirin require dose modification in patients with moderate to severe CKD Nephrolithiasis, CKD, and acute interstitial nephritis have been reported with protease inhibitors Acute kidney injury has been reported with remdesivir in patients with severe COVID-19 Pharmacokinetic-enhanced protease inhibitors increase the concentration of some drugs such as statins, cinacalcet, steroids, calcineurin inhibitors (CNIs) Some hypothetical benefits and harms have been suggested for statins and renin-angiotensinaldosterone system inhibitors in COVID-19 patients Continuing guideline-directed administration of these drugs is recommended Among different immunomodulating/immunosuppressive drugs, hydroxychloroquine and CNIs are the safest ones during COVID-19 Antimetabolites are suggested to be withheld during moderate to severe COVID-19 Fluid therapy and anticoagulant prophylaxis/ treatment need special attention in CKD patients with COVID-19 CKD patients with COVID-19 are treated as other patients, with some dose modifications if needed Be mindful for management of drug interactions as well as modification of immunosuppressive drugs in patients with moderate to severe COVID-19
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #643618
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Sexual Dysfunction in Female Hemodialysis Patients

Seyed Mansour Gatmiri / Marjan Bordbar / Firoozeh Raisi / Anahid Nourian

Acta Medica Iranica, Vol 57, Iss

A Cross Sectional Study in Iran

2019 Volume 4

Abstract: There has been little attention to sexual dysfunction (SD) in women undergoing hemodialysis (HD), therefore few studies are found in this field. The aim of this study was to determine the incidence of SD, assess its association with biochemical factors, ... ...

Abstract	There has been little attention to sexual dysfunction (SD) in women undergoing hemodialysis (HD), therefore few studies are found in this field. The aim of this study was to determine the incidence of SD, assess its association with biochemical factors, employment and educational status, economic situation, depression, anxiety, and medication. End stage renal disease (ESRD) married women aged 18 to 60 years presenting to Tehran University of Medical Sciences (TUMS) hospitals’ (Imam Khomeini, Sina, and Baharloo) from April to September 2017 were included in the study. Female Sexual Function Index (FSFI) questionnaire was used to evaluate SD. Patients were divided into two groups with SD (scores≤28) and without SD (scores˃28). Hospital Anxiety and Depression Scale (HADS) questionnaire was used to investigate anxiety and depression; patients with scores equal to or more than 11 were implied as depressed or anxious. Demographic data, duration of dialysis, ESRD causes and biochemical tests were also collected. Thirty patients (81.1%) out of 37 showed SD who were older, had lower educational and economic status, had higher hemoglobin levels and used erythropoietin products and Venofer® (iron sucrose injection) less; most of these patients were housewives. The incidence of SD among patients was high. Erythropoietin and Venofer use was less frequent in patients with SD compared to the other group. This suggests that these two products have a role in treatment of SD rather than the treatment of anemia.
Keywords	ESRD ; HD ; SD ; Erythropoietin ; Venofer ; Sexual dysfunction ; Medicine (General) ; R5-920
Subject code	616
Language	English
Publishing date	2019-07-01T00:00:00Z
Publisher	Tehran University of Medical Sciences
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Metoclopramide as intermittent and continuous infusions in critically ill patients: a pilot randomized clinical trial.

Malekolkottab, Masoume / Khalili, Hossein / Mohammadi, Mostafa / Ramezani, Masoud / Nourian, Anahid

Journal of comparative effectiveness research

2017 Volume 6, Issue 2, Page(s) 127–136

Abstract: Aim: Metoclopramide is commonly used as a prokinetic agent in critically ill patients with enteral feeding intolerance. In this study, noninferiority of metoclopramide as intermittent versus continuous infusion was examined in critically ill patients ... ...

Abstract	Aim: Metoclopramide is commonly used as a prokinetic agent in critically ill patients with enteral feeding intolerance. In this study, noninferiority of metoclopramide as intermittent versus continuous infusion was examined in critically ill patients with enteral feeding intolerance. Methods: Forty critically ill adults patients were assigned to receive metoclopramide as either intermittent (10 mg every 6 h) or continuous (2 mg/h) infusion. Frequency of feeding intolerance and adverse effects of metoclopramide were assessed during 7 days of study. Results: Number of patients with feeding intolerance during different times of the course was not different between the groups. Although not statistically significant, diarrhea and cardiac rhythm were more common in continuous than intermittent infusion group. Conclusion: Continuous and intermittent infusions of metoclopramide showed equivalent effectiveness in critically ill patients.
Language	English
Publishing date	2017-03
Publishing country	England
Document type	Journal Article
ISSN	2042-6313
ISSN (online)	2042-6313
DOI	10.2217/cer-2016-0067
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial.

Khalili, Hossein / Nourian, Anahid / Ahmadinejad, Zahra / Emadi Kouchak, Hamid / Jafari, Sirous / Dehghan Manshadi, Sayed Ali / Rasolinejad, Mehrnaz / Kebriaeezadeh, Abbas

Acta bio-medica : Atenei Parmensis

2020 Volume 91, Issue 4, Page(s) e2020102

Abstract: Background: There is no study regarding the use of SOF/LDP in treatment of COVID-19. Objectives: In this study, the efficacy and safety of SOF/LDP were assessed in treatment of patients with mild to moderate COVID-19.: Methods: Among an open-label ... ...

Abstract	Background: There is no study regarding the use of SOF/LDP in treatment of COVID-19. Objectives: In this study, the efficacy and safety of SOF/LDP were assessed in treatment of patients with mild to moderate COVID-19. Methods: Among an open-label randomized clinical trial, 82 patients with mild to moderated COVID-19 were assigned to receive either SOF/LDP 400/100 mg daily plus the standard of care (SOF/LDP group, n=42) or the standard of care alone (control group, n=40) for 10 days. Time to clinical response, rate of clinical response, duration of hospital and ICU stay and 14-day mortality were assessed. Results: Clinical response occurred in 91.46% of patients. Although rates of clinical response were comparable between the groups but it occurred faster in the SOF/LDP group than the control group (2 vs. 4 days respectively, P= 0.02). Supportive cares were provided in the medical wards for most patients but 17.07% of patients were transferred to ICU during the hospitalization course. However, durations of hospital and ICU stay were comparable between the groups. 14--day mortality rate was 7.14% and 7.5% in the SOF/ LDP and control groups respectively. No adverse effects leading to drug discontinuation occurred. Gastrointestinal events (nausea, vomiting and diarrhea) were the most common side effects (15.85%). Conclusion: Added to the standard of care, SOF/LDP accelerated time to the clinical response. However, rate of clinical response, duration of hospital and ICU stay and 14-day mortality were not different. No significant adverse event was detected. More randomized clinical trials with larger sample sizes are needed to confirm the efficacy and safety of SOF/LDP in the treatment of COVID-19.
MeSH term(s)	Aged ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Benzimidazoles/adverse effects ; Benzimidazoles/therapeutic use ; COVID-19/drug therapy ; Drug Combinations ; Fluorenes/adverse effects ; Fluorenes/therapeutic use ; Humans ; Middle Aged ; Severity of Illness Index ; Sofosbuvir/adverse effects ; Sofosbuvir/therapeutic use ; Treatment Outcome
Chemical Substances	Antiviral Agents ; Benzimidazoles ; Drug Combinations ; Fluorenes ; ledipasvir, sofosbuvir drug combination ; Sofosbuvir (WJ6CA3ZU8B)
Language	English
Publishing date	2020-11-10
Publishing country	Italy
Document type	Journal Article ; Randomized Controlled Trial
ZDB-ID	2114240-3
ISSN	2531-6745 ; 0392-4203
ISSN (online)	2531-6745
ISSN	0392-4203
DOI	10.23750/abm.v91i4.10877
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 925: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial.

Toroghi, Negar / Abbasian, Ladan / Nourian, Anahid / Davoudi-Monfared, Effat / Khalili, Hossein / Hasannezhad, Malihe / Ghiasvand, Fereshteh / Jafari, Sirous / Emadi-Kouchak, Hamid / Yekaninejad, Mir Saeed

Pharmacological reports : PR

2021 Volume 74, Issue 1, Page(s) 229–240

Abstract: Background and objectives: Corticosteroids are commonly used in the treatment of hospitalized patients with COVID-19. The goals of the present study were to compare the efficacy and safety of different doses of dexamethasone in the treatment of patients ...

Abstract	Background and objectives: Corticosteroids are commonly used in the treatment of hospitalized patients with COVID-19. The goals of the present study were to compare the efficacy and safety of different doses of dexamethasone in the treatment of patients with a diagnosis of moderate to severe COVID-19. Methods: Hospitalized patients with a diagnosis of moderate to severe COVID-19 were assigned to intravenous low-dose (8 mg once daily), intermediate-dose (8 mg twice daily) or high-dose (8 mg thrice daily) dexamethasone for up to 10 days or until hospital discharge. Clinical response, 60-day survival and adverse effects were the main outcomes of the study. Results: In the competing risk survival analysis, patients in the low-dose group had a higher clinical response than the high-dose group when considering death as a competing risk (HR = 2.03, 95% CI: 1.23-3.33, p = 0.03). Also, the survival was significantly longer in the low-dose group than the high-dose group (HR = 0.36, 95% CI = 0.15-0.83, p = 0.02). Leukocytosis and hyperglycemia were the most common side effects of dexamethasone. Although the incidence was not significantly different between the groups, some adverse effects were numerically higher in the intermediate-dose and high-dose groups than in the low-dose group. Conclusions: Higher doses of dexamethasone not only failed to improve efficacy but also resulted in an increase in the number of adverse events and worsen survival in hospitalized patients with moderate to severe COVID-19 compared to the low-dose dexamethasone. (IRCT20100228003449N31).
MeSH term(s)	Adult ; Aged ; Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Anti-Inflammatory Agents/therapeutic use ; COVID-19/drug therapy ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Dexamethasone/therapeutic use ; Dose-Response Relationship, Drug ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Female ; Humans ; Hyperglycemia/chemically induced ; Incidence ; Leukocytosis/chemically induced ; Male ; Middle Aged ; Survival Analysis ; Treatment Outcome
Chemical Substances	Anti-Inflammatory Agents ; Dexamethasone (7S5I7G3JQL)
Language	English
Publishing date	2021-11-27
Publishing country	Switzerland
Document type	Comparative Study ; Journal Article ; Randomized Controlled Trial
ZDB-ID	2186248-5
ISSN	1734-1140
ISSN	1734-1140
DOI	10.1007/s43440-021-00341-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 861: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito